Movers and SHAKERS
PDS Biotechnology Corp (PDSB)
PDS's Diverse Portfolio in Broad Therapeutic Areas Is Highly Appealing
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
What do we like? The applicability of the platform technology. In our view, PDS remains under the Street's radar with a clinical pipeline as well as a versatile technology platform enabling growth in new directions. As we look forward, we believe that both oncology and infectious disease portfolios may provide dynamic catalysts for the medium term, while the technology platform with multiple Phase 2 clinical trials provides fundamental depth to future value.
Portfolio diversification is utmost in the near-term. The value-generating catalyst in the near-tear is predominantly based on the commencement of two Phase 2 clinical trials in Q4 2020 - PDS0101 for the treatment of i) recurrent/metastatic head and neck cancer (HNC) and ii) advanced cervical cancers. The company also broadened infectious disease programs to include the development of vaccines for ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.